J.P. Morgan Notebook, Jan. 11: Pfizer/Allergan, Celgene, Gilead And More
This article was originally published in The Pink Sheet Daily
Daily round-up of news and notes from the 2016 J.P. Morgan Healthcare Conference in San Francisco.
You may also be interested in...
With proof of high response rates in small studies of B-cell malignancies in the rear view, sponsors focus on the next hurdles – launching potentially registrational studies in 2015, honing plans for a smooth-running manufacturing process and branching out into new indications.
The virtual J.P. Morgan Healthcare meeting was missing the usual energy but still had substance.
CEO Amit Munshi told the J.P. Morgan meeting the company will double the size of its clinical-stage cardiovascular disease pipeline with the addition of temanogrel.